Table 3 Comparison of the baseline characteristics of responders within the first three months of erenumab treatment versus non-responders
From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Characteristic | Responders (n = 64) | Non-respondersa (n = 25) | P value |
|---|---|---|---|
Female, n (%) | 54 (84.4) | 24 (96.0) | 0.134 |
Age, median (IQR) | 48 (38–52.5) | 52.5 (42–56) | 0.358 |
Years of migraine history, median (IQR) | 28 (19.5–34.5) | 25 (18–32) | 0.467 |
MMDs, median (IQR) | 18 (12–27.5) | 26.5 (20–30) | 0.026 |
Analgesic days, median (IQR) | 8 (2.5–22) | 20 (11–29) | 0.008 |
Triptan days, median (IQR) | 3 (0–16.5) | 1 (0–20) | 0.532 |
Chronic migraine, n (%) | 59 (92.2) | 25 (100.0) | 0.150 |
Aura, n (%) | 18 (28.1) | 9 (36.0) | 0.468 |
Allodynia, n (%) | 23 (35.9) | 10 (40.0) | 0.721 |
Medication overuse, n (%) | 45 (70.3) | 19 (76.0) | 0.592 |
Prior preventive treatment failures, n (%) | Â | Â | 0.560 |
 2 | 18 (28.1) | 10 (40.0) |  |
 > 2 | 46 (71.9) | 15 (60.0) |  |
Botulinum toxin failure, n (%) | 31 (48.4) | 13 (52.0) | 0.763 |